ACM
IGMS

AlphaCrest Capital Management’s IGM Biosciences IGMS Stock Holding History

AlphaCrest Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,000
Closed -$250K – 1307
2021
Q2 		$250K Buy
+3,000
New +$222K 0.01% 1156

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AlphaCrest Capital Management's IGMS Position: Q3 2021 in Review

AlphaCrest Capital Management sold out of IGM Biosciences (IGMS) in Q3 2021, closing a stake of 3,000 shares — an estimated $250K sold.

AlphaCrest Capital Management first reported a position in IGMS in Q2 2021 and held it in 1 quarter. The position peaked at $250K in Q2 2021. 107 funds tracked by Wall St. Rank hold IGMS as of Q3 2021.

  • AlphaCrest Capital Management reported no remaining IGM Biosciences position as of Q3 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 3,000 IGM Biosciences shares in Q3 2021, an estimated $250K.
  • AlphaCrest Capital Management first reported a position in IGM Biosciences in Q2 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's IGM Biosciences position peaked at $250K in Q2 2021.
  • 107 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2021.

Based on AlphaCrest Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.